Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease

Abstract

Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease F3 13. Dual antiplatelet therapy in patients with acute coronary syndrome not treated with revascularisation 14. Dual antiplatelet therapy in elderly and frail patients 14.1 Dual antiplatelet therapy in the elderly person 14.1.1 Antiplatelet drugs 14.1.2 P2Y 12 receptor antagonists 14.1.3 Dual antiplatelet therapy in elderly patients on oral anticoagulant therapy 14.1.4 Duration of dual antiplatelet therapy 14.2 Dual long-term antiplatelet therapy in the frail patient 14.3 Conclusions 15. Dual antiplatelet therapy in diabetic patients and/or those with renal dysfunction 15.1 Atherothrombotic risk in diabetic patients 15.1.1 Which anti-thrombotic therapy in diabetic patients? 15.1.2 Duration of dual antiplatelet therapy in diabetic patients 15.2 Atherothrombotic risk in patients with renal insufficiency 15.2.1 Anti-thrombotic therapy in patients with acute coronary syndrome and chronic renal failure 15.2.2 Dual antiplatelet therapy prolonged beyond 12 months after acute coronary syndrome in patients with chronic renal failure 16. Dual antiplatelet therapy in patients with peripheral obliterative arteriopathy 16.1 Epidemiological background 16.2 Dual antiplatelet therapy in patients with peripheral obliterative arteriopathy 16.3 Indications in the guidelines 16.4 Conclusions 17. Duration of dual antiplatelet therapy in patients with recurrent ischaemic events 17.1 Recurrence events in the first year following acute coronary syndrome 17.2 Recurrence events beyond the first year following acute coronary syndrome 18. Dual antiplatelet therapy in patients receiving oral anticoagulation 19. Dual antiplatelet therapy in patients at high bleeding risk 19.1 How to reduce the risk of bleeding in high-risk patients 20. Dual antiplatelet therapy in patients undergoing a preoperative cardiovascular evaluation for non-cardiac surgery 21. Management of patients who develop haemorrhages during dual antiplatelet therapy 21.1 Bleeding during dual antiplatelet therapy 21.2 Indication for dual antiplatelet therapy 21.3 Haemorrhage management 21.4 Grades of dual antiplatelet therapy 21.5 Resumption of dual antiplatelet therapy CSC